<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029752</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1309</org_study_id>
    <nct_id>NCT05029752</nct_id>
  </id_info>
  <brief_title>Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)</brief_title>
  <official_title>Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Vendys II, an FDA-approved device, uses finger digital thermal monitoring (DTM) after a&#xD;
      period of blood flow restriction to evaluate vascular health. This study will evaluate the&#xD;
      feasibility of using this device to measure the Vascular Reactivity Index (VRI) in children&#xD;
      and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      -Assess the feasibility of the use of VENDYS-II in children and AYA as a measure of vascular&#xD;
      endothelial function, where feasibility is defined as completion of the evaluation by at&#xD;
      least 70% of consented participants.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      -Summarize the incidence of any adverse events that precludes completion of assessment of&#xD;
      endothelium-dependent vasodilation using the Vendys II in children and AYA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The use of VENDYS-II in children and AYA as a measure of vascular endothelial function.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vascular</condition>
  <condition>Endothelial</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Endothelix</condition>
  <arm_group>
    <arm_group_label>Vendys II Device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Your participation in this study will be over after your blood vessel health is measured 1 time with the Vendys II device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vendys II Device</intervention_name>
    <description>Using the device</description>
    <arm_group_label>Vendys II Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for HCT candidates:&#xD;
&#xD;
          -  Children, adolescents and young adults (AYA) 6-26 years of age who are HCT candidates&#xD;
&#xD;
          -  Recipients within 30 days prior to or within 14 days after autologous and allogeneic&#xD;
             HCT.&#xD;
&#xD;
             -. Any preparative regimen.&#xD;
&#xD;
          -  Willing and eligible to enroll on PA19-0756&#xD;
&#xD;
        Inclusion Criteria for Healthy Donors:&#xD;
&#xD;
        - Healthy HCT donors between the ages of 6-26 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any subject who does not consent/assent to participation.&#xD;
&#xD;
             -. Any subject with an injury or deformation to the index finger which prevents proper&#xD;
             fit of the device.&#xD;
&#xD;
          -  Any subject with skin toxicity or neuropathy which prevents comfortable use of the&#xD;
             device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris Mahadeo</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kris Mahadeo</last_name>
    <phone>(713) 792-2873</phone>
    <email>kmmahadeo@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Mahadeo</last_name>
      <phone>713-792-2873</phone>
      <email>kmmahadeo@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

